BRCA revision mutations may explain some of the limited benefit seen in long-term follow-up studies with PARP inhibitors.

Bibliography:

1: BRCA reversion mutations predict resistance. https://doi.org/10.1158/2159-8290.CD-18-0715

2: SOLO3 Final OS Data. https://doi.org/10.1200/JCO.24.00933

3: Elucidating acquired PARP inhibitor resistance in advanced prostate cancer. https://doi.org/10.1016/j.ccell.2024.10.015

Recapping HOPA 25 and Portland

*Great food (not discussed, the most excellent ETSU dinner at Arden)

*COCOON

*Pharmacists make everyone's job easier and keep patients out of the ED

*A few more tidbits too!

FDA expands approvals for durvalumab (bladder cancer) and Lutetium-177 vipivotide tetraxetan (pre-taxane in metastatic prostate cancer). Portland has places.

A Foundations of OncoPharm episode on Topotecan. (Originally to be released week of 3/27)

We discuss reduced dose apixaban for months 6+ of treating cancer-associated VTE (API-CAT) and the impact (or lack thereof) of pausing BTK-inhibitors around vaccination (IMPROVE)

The updated Keynote 811 OS results convert an accelerated approval for pembrolizumab to a regular approval, albeit restricted by PD-L1 CPS status of 1 or higher.

There is a decent track record with mixed results for cryotherapy to prevent taxane-induced peripheral neuropathy. The POLAR trial adds to this body of evidence that trends in favor of cryotherapy. Compression therapy is another alternative. Both are studied in POLAR.

POLAR: doi:10.1001/jamaoncol.2025.0001

Ten of the top herb-chemotherapy interactions.

About Herbs website: https://www.mskcc.org/cancer-care/diagnosis-treatment/symptom-management/integrative-medicine/herbs/search

Also, search 'About Herbs' in your app store.

Two recent publications suggest modifications to standard subcutaneous daratumumab pre-meds is safe...and saves time!

Padmaraju et al experience from Chicago Med Center: https://doi.org/10.1093/oncolo/oyae158

Vazirnia et al experience from Mayo Clinic: https://doi.org/10.1200/OP.23.00470

We end summarizing some emerging evidence about the need, or lack thereof, for pre-paclitaxel H2RAs.

We take a deep look at the recently published, and guideline changing, AMPLIFY trial of fixed-duration acalabrutinib in CLL.

Link: DOI: 10.1056/NEJMoa2409804